Technology for minimally invasive surgery of tear drainage system secures $1.2 million

Company name: Sinopsys Surgical, also known as DCS Surgical Inc.

Industry: Medical devices (surgery).

presented by

Sponsored Post

Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork 

By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.

By Michael Blackman, MD, MBA Chief Medical Officer, Greenway Health®

Location: Boulder, Colorado.

Solution/product: Currently in stealth mode, the company is developing minimally invasive surgical technology for the lacrimal system, which comprises structures for tear production and drainage.

Money raised: Half of a $2.4 million equity offering.

Investors: The U.S. Securities and Exchange Commission filing lists directors from DFJ Mercury, High Country Venture and Aweida Venture Partners.

presented by

Sponsored Post

Join us June 17th as we explore how a unified identity strategy, spanning patients, providers, and emerging solutions like Verato Identity Network enables accurate attribution, strengthens interoperability, and ultimately drives VBC success.

By Verato and MedCity News

Management team: CEO Harry Ross is a former partner at Aweida Venture Partners.

Competitors: Quest Medical, FCI Ophthalmics and Sterimedix also make devices for blocked tear ducts.